Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Carnegie recognised as Best Investment Bank in Sweden & Denmark

Following a global survey by international business magazine Euromoney, Carnegie was recognised as the Best Investment Bank in both Sweden and Denmark.Carnegie was named Best Investment Bank in both Sweden and Denmark as competences within financing, advisory and markets were collectively assessed for each market. The recognition was announced in London on Wednesday, July 11 and is based on over 1,500 submissions from banks around the world competing for global, regional and national titles. The annual assessment covers a review of thousands of global banks and their ability to deliver

Risk Intelligence approved for listing on Spotlight Stock Market

Risk Intelligence A/S is a global provider of security intelligence, which includes recommendations and critical information about security threats and risks in hotspots around the world. The main purpose of listing on Spotlight is to finance planned growth. The company will be Spotlight's second company traded in Danish kroner, following Freetrailer's launch in June 2018.Risk Intelligence was founded in Denmark in 2001 and has grown to become a global provider of threat- and risk assessments for companies operating in shipping, offshore, oil and gas. Risk Intelligence provides assessments

#18-1206 Recalculation of reference value for certain instruments with ICE Brent Crude Oil as underlying security

The reference value for certain certificates with ICE Brent Crude Oil as underlying has been recalculated in accordance with the instruments final terms. This applies to the following instruments:Symbol: BULL OLJA X15 VON2 Symbol: BULL OLJA X15 VON4 Symbol: BULL OLJA X15 VON5 Symbol: BULL OLJY X15 V Symbol: BULL OLJY X15 V2 Symbol: BULL OLJY X15 V3 Symbol: BULL OLJY X15 V4 Symbol: BULL OLJY X15 V5 Symbol: BULL OLJA X12 VON3 Symbol: BULL OLJA X12 VON4 Symbol: BULL OLJA X12 VON5 Symbol: BULL OLJY X12 V3 Symbol: BULL OLJY X12 V4 Symbol: BULL OLJA X12 V5

CORRECTION: TOMRA: INVITATION TO 2Q 2018 PRESENTATION

TOMRA's second quarter 2018 results will be released Thursday 19th of July 2018. President & CEO Stefan Ranstrand and CFO Espen Gundersen will present the results at 08:00 CET. The presentation will be held in English. The presentation will be sent via live webcast only. Questions can be directed to the speaker via the Q&A tool embedded in the webcast and will be addressed after the presentation. Link to the live broadcast will be available on www.tomra.com (Investor Relations section). A recorded version of the webcast will be available after the broadcast has concluded. All written

Extension of standstill and deferral agreement for Solship Invest 3 AS

Reference is made to the stock exchange announcement of July 6th, 2018, in which it was informed that Solship Invest 3 AS and its subsidiaries had entered into an agreement with its major financial creditors to postpone instalment and interest payments until July 11th, 2018. Solship Invest 3 AS and its subsidiaries have received consent from the relevant financial creditors to extend the agreement until July 20th, 2018. Skudeneshavn, July 12th, 2018 ContactsLars Peder Solstad CEO, at +47 91 31 85 85Anders Hall Jomaas CFO, at +47 40 04 29 18 Solstad Farstad ASAwww.

Scientists at UCSF-PHI Center of Excellence map the genetic progression of invasive skin cancer

Utilizing precision genetic engineering and PHI’s HoloMonitor technology, scientists at University of California, San Francisco, have for the first time been able to monitor and map how mutations break down the genetic protection against skin cancer, allowing harmless moles to transform into invasive skin cancer. The new research, which promises to improve skin cancer treatment by allowing malignant forms to be identified earlier, was recently published in two companion papers in the prestigious and high impact scientific journal Cancer Cell. “It is our role and vision to

Intervacc recieves funding from Eurostars for further development of vaccine for piglets.

Intervacc has been awarded funding through the Eurostars-2 program for further development of a vaccine against severe infection of piglets caused by Streptococcus suis. The Eurostars-2 program, a part of EU:s Horizon 2020, thus finances approximately 50% of the budgeted project cost of approximately € 1.6 million and at the same time adds a significant quality approval for the exciting vaccine technology. "Funding from Eurostars, in fierce competition with many other projects, confirms the strength of Intervacc, our technology and our business strategy to develop new vaccines in animal

Recurring revenues in strong growth

Summary for January-June 2018 · Net sales MSEK 465 (388) · Profit before tax MSEK 48,1 (54,2) · Operating margin 11,4 % (14,9) · Earnings per share before dilution SEK 1,29 (1,44) · Cash flow from operations MSEK 119,8 (134,1) Summary for April-June 2018 · Net sales MSEK 243 (197) · Profit before tax MSEK 23,0 (29,8) · Operating margin 10,7 % (16,1) · Earnings per share before dilution SEK 0,62 (0,80) · Cash flow from operations MSEK 6,9 (35,3) · Acquisition of PP7 Affärssystem AB, Agrando AS and Cito IT A/SCEO’s comments Recurring revenues grew by

Henrik Wennerholm appointed CEO of DDM

DDM Holding AG (First North: DDM) announces that the board has today appointed Henrik Wennerholm as Chief Executive Officer of DDM with immediate effect. Henrik joined DDM in May 2018 as Head of Business Development and is a member of the Executive Management Committee.“Having founded his own company within the non-performing loans industry, which was later sold to B2Holding, Henrik has the right background and experience to lead DDM in the next phase of development”, says Torgny Hellström, Chairman of the Board of DDM Holding AG. “I am excited to lead and further develop DDM. There are

Vestas to deliver 112 MW turnkey solution for Palisade’s Granville Harbour Wind Farm, will power more than 46,000 Tasmanian households

News release from Vestas Asia Pacific Singapore, 12 July 2018  Australian-based Palisade Investment Partners Limited (Palisade) has placed a 112 MW turnkey order with Vestas for the Granville Harbour Wind Farm in Tasmania, Australia. Vestas has developed a solution with Palisade that is customised to Tasmania’s excellent wind conditions, and that will provide low-cost renewable energy that can power more than 46,000 local homes. The project supports both Tasmania’s ambitious target to be self-sufficient with renewable energy and Tasmania’s role within the National Electricity Market

Interim Report January-June 2018

Second quarter 2018 compared to second quarter 2017 · Customer growth remained positive at 23,300 (27,900) despite an unsettled market · Net inflow in the quarter was SEK 4,840 million (8,710). The share of net inflow from existing customers decreased · Operating income increased by 4 per cent, mainly due to higher fund volymes and, as a result, higher fund commissions. Brokerage income decreased due to lower turnover · Operating expenses increased by 17 per cent. The cost increase is a result of expanded development capacity for future growth, where a larger share than

SinterCast posts record series production in second quarter

· Record annualised series production of 2.7 million Engine Equivalents in second quarter · First half production up 24% following two consecutive quarters of record production · Record Sampling Cup shipments in second quarter and for the first half of 2018[Stockholm, 12 July 2018] – Annualised series production reached 2.7 million Engine Equivalents in the second quarter of 2018, surpassing the previous record of 2.5 million Engine Equivalents set in the first quarter. Following two consecutive quarters of record series production, year-on-year production is up 24% at the half-year

TOMRA: INVITATION TO 2Q 2018 PRESENTATION

TOMRA's second quarter 2018 results will be released Friday 19th of July 2018. President & CEO Stefan Ranstrand and CFO Espen Gundersen will present the results at 08:00 CET. The presentation will be held in English. The presentation will be sent via live webcast only. Questions can be directed to the speaker via the Q&A tool embedded in the webcast and will be addressed after the presentation. Link to the live broadcast will be available on www.tomra.com (Investor Relations section). A recorded version of the webcast will be available after the broadcast has concluded. All written

Hansa Medical to Host Conference Call to Provide Second Quarter 2018 Business Update

On 19 July 2018, at 08:00AM CET, Hansa Medical will publish its Business Update for the second quarter of 2018. All interested parties are invited to participate in a telephone conference, which will include a presentation, on the same day at 2:00PM CET. The event will be hosted by Hansa Medical’s CEO and President, Søren Tulstrup, and the presentation will be held in English.Slides used in the presentation will be live on the company’s website during the call under Events & Webcast and will also be made available online after the call. To participate in the telephone conference, please use

Axis AB: Half-year report January-June 2018

Second quarter · Net sales increased during the second quarter by 23 percent to SEK 2,601 M (2,119). Net sales increased by 25 percent in local currencies. · Operating profit amounted to SEK 429 M (209), which corresponds to an operating margin of 16.5 percent (9.9). · Net profit for the period amounted to SEK 331 M (149). · Earnings per share amounted to SEK 4.77 (2.14). The first half of 2018 · Net sales increased during the period by 12 percent to SEK 4,659 M (4,146). Net sales increased by 17 percent in local currencies. · Operating profit amounted to SEK 607 M (

Alligator Bioscience AB Interim Report January-June 2018

Positive data for our preclinical projectsSignificant events April-June• The ADC-1013 clinical phase I study performed by Janssen is ongoing with more than 80 patients recruited and the technology transfer to Biogen Inc. for the production of clinical material has been completed.Preclinical data presented at scientific conferences:• ATOR-1015 localizes to the tumor and selectively activates the immune system in the tumor, confirming the intended mechanism of action.• ATOR-1017 potently activates T cells and NK cells, both important for immune-mediated tumor cell killing. The results

Citycon Oyj’s Half-Yearly Report for 1 January – 30 June 2018: Solid operating performance continued; earnings impacted by disposals and FX

Citycon Oyj   Half-Yearly Report   12 July 2018 at 09:00 hrs-Economic occupancy rate improved by 30 basis points.-Divestments conducted in 2017 and in H1/2018 as well as weaker currencies impacted net rental income and EPRA Earnings as expected. Cost savings initiatives progressed well and administrative expenses decreased by 10% year-on-year.-Good operating performance in shopping centre Iso Omena continued: strong footfall and tenant sales.-Fair value change of investment properties was EUR -34 million mainly driven by Finland and Norway.-Guidance related to Direct operating

Interim report January-June 2018

Quarter 2, 2018 · Incoming orders amounted to SEK 912.1m (849.4), which organically is a decrease of 1.3 percent compared with the same period last year. · Net sales amounted to SEK 863.9m (759.2), which organically is an increase of 5.2 percent compared with the same period last year. · Adjusted operating profit was SEK 70.4m (60.9), giving an adjusted operating margin of 8.1 percent (8.0). · Operating profit was SEK 66.6m (60.9), giving an operating margin of 7.7 percent (8.0). · Net profit was SEK 43.8m (38.3). · Earnings per share were SEK 1.25 kr (1.09).* January

Oura Health strengthens its position in the US market

Company moves to 12.5M€ in total private funding and appoints new board members with US industry expertise for latest growth phaseOura Health , the Finnish health technology company behind the Oura ring, has moved its total private funding to 12.5M€ after the closure of a round led by US-based Bold Capital Partners  and Finland’s Tesi . The funding will be used to scale US market operations and push the Oura platform forward. The Oura ring and app guides wearers towards better sleep, recovery

Personal customers and businesses borrow more

DNB recorded profits of NOK 6 084 million in the second quarter of 2018, up NOK 847 millionfrom the second quarter of 2017. Loans to personal customers have increased by NOK 36 billion during the past year. The Norwegian economy is still on the right course and contributed to yet another strong performance by DNB. Low losses and stable income are the main factors influencing the results for the first half of the year.   “Though times are good, this does not automatically generate results. We are gratified that we are an attractive bank for those who wish to realise their housing

Publishing of YIT Corporation's Half-Year Report for January–June 2018 on July 26, 2018

YIT Corporation Investor News July 12, 2018 at 8:00 a.m.YIT Corporation's Half-Year Report for January–June 2018 will be published on Thursday, July 26, 2018 at approximately 8:00 a.m. Finnish time (EEST, approx. 6:00 a.m. BST). The stock exchange release and the presentation materials in Finnish and in English will be published at that time on the company's website at www.yitgroup.com/investors. News conference for investors and media YIT will arrange a news conference on Thursday, July 26, 2018 at 10:00 a.m. Finnish time (EEST, at 8:00 a.m. BST) at YIT's head office, Panuntie 11,

Aker Solutions ASA: Second-Quarter and Half-Year Results 2018

July 12, 2018 2Q 2018 Financial Highlights · Revenue NOK 6.3 billion · EBITDA NOK 439 million · EBITDA margin 7% · EBITDA ex. special items NOK 441 million · EBITDA margin ex. special items 7.1% · Earnings per share ex. special items NOK 0.48 · Order intake NOK 5.7 billion · Order backlog NOK 37 billion Aker Solutions' earnings strengthened in the second quarter of 2018 as orders almost doubled from a year earlier amid a pickup in activity. The company delivered strong execution on major projects globally and made good progress on the second phase of its

Valuation of D. Carnegie & Co's property portfolio will have positive impact on Q2 2018 earnings

D. Carnegie & Co has, in line with its approach historically, had Savills perform a market valuation of 100% of the company’s property portfolio as per 30 June 2018. D. Carnegie & Co's continued comprehensive, value-creating investment program, progress on its building rights, and the increasingly strong investor interest in Swedish residential assets, have resulted in an increased valuation of D. Carnegie & Co's property portfolio. This has led to a positive impact of approximately SEK 1.8 billion on the pre-tax profit in the second quarter of 2018. “The valuation increase is a result

There are no items matching the current filter
There are no more items matching the current filter
Back to top